Conservative management versus tonsillectomy in adults with recurrent acute tonsillitis in the UK (NATTINA): a multicentre, open-label, randomised controlled trial.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
17 06 2023
Historique:
received: 02 03 2022
revised: 03 02 2023
accepted: 02 03 2023
medline: 19 6 2023
pubmed: 21 5 2023
entrez: 20 5 2023
Statut: ppublish

Résumé

Tonsillectomy is regularly performed in adults with acute tonsillitis, but with scarce evidence. A reduction in tonsillectomies has coincided with an increase in acute adult hospitalisation for tonsillitis complications. We aimed to assess the clinical effectiveness and cost-effectiveness of conservative management versus tonsillectomy in patients with recurrent acute tonsillitis. This pragmatic multicentre, open-label, randomised controlled trial was conducted in 27 hospitals in the UK. Participants were adults aged 16 years or older who were newly referred to secondary care otolaryngology clinics with recurrent acute tonsillitis. Patients were randomly assigned (1:1) to receive tonsillectomy or conservative management using random permuted blocks of variable length. Stratification by recruiting centre and baseline symptom severity was assessed using the Tonsil Outcome Inventory-14 score (categories defined as mild 0-35, moderate 36-48, or severe 49-70). Participants in the tonsillectomy group received elective surgery to dissect the palatine tonsils within 8 weeks after random assignment and those in the conservative management group received standard non-surgical care during 24 months. The primary outcome was the number of sore throat days collected during 24 months after random assignment, reported once per week with a text message. The primary analysis was done in the intention-to-treat (ITT) population. This study is registered with the ISRCTN registry, 55284102. Between May 11, 2015, and April 30, 2018, 4165 participants with recurrent acute tonsillitis were assessed for eligibility and 3712 were excluded. 453 eligible participants were randomly assigned (233 in the immediate tonsillectomy group vs 220 in the conservative management group). 429 (95%) patients were included in the primary ITT analysis (224 vs 205). The median age of participants was 23 years (IQR 19-30), with 355 (78%) females and 97 (21%) males. Most participants were White (407 [90%]). Participants in the immediate tonsillectomy group had fewer days of sore throat during 24 months than those in the conservative management group (median 23 days [IQR 11-46] vs 30 days [14-65]). After adjustment for site and baseline severity, the incident rate ratio of total sore throat days in the immediate tonsillectomy group (n=224) compared with the conservative management group (n=205) was 0·53 (95% CI 0·43 to 0·65; <0·0001). 191 adverse events in 90 (39%) of 231 participants were deemed related to tonsillectomy. The most common adverse event was bleeding (54 events in 44 [19%] participants). No deaths occurred during the study. Compared with conservative management, immediate tonsillectomy is clinically effective and cost-effective in adults with recurrent acute tonsillitis. National Institute for Health Research.

Sections du résumé

BACKGROUND
Tonsillectomy is regularly performed in adults with acute tonsillitis, but with scarce evidence. A reduction in tonsillectomies has coincided with an increase in acute adult hospitalisation for tonsillitis complications. We aimed to assess the clinical effectiveness and cost-effectiveness of conservative management versus tonsillectomy in patients with recurrent acute tonsillitis.
METHODS
This pragmatic multicentre, open-label, randomised controlled trial was conducted in 27 hospitals in the UK. Participants were adults aged 16 years or older who were newly referred to secondary care otolaryngology clinics with recurrent acute tonsillitis. Patients were randomly assigned (1:1) to receive tonsillectomy or conservative management using random permuted blocks of variable length. Stratification by recruiting centre and baseline symptom severity was assessed using the Tonsil Outcome Inventory-14 score (categories defined as mild 0-35, moderate 36-48, or severe 49-70). Participants in the tonsillectomy group received elective surgery to dissect the palatine tonsils within 8 weeks after random assignment and those in the conservative management group received standard non-surgical care during 24 months. The primary outcome was the number of sore throat days collected during 24 months after random assignment, reported once per week with a text message. The primary analysis was done in the intention-to-treat (ITT) population. This study is registered with the ISRCTN registry, 55284102.
FINDINGS
Between May 11, 2015, and April 30, 2018, 4165 participants with recurrent acute tonsillitis were assessed for eligibility and 3712 were excluded. 453 eligible participants were randomly assigned (233 in the immediate tonsillectomy group vs 220 in the conservative management group). 429 (95%) patients were included in the primary ITT analysis (224 vs 205). The median age of participants was 23 years (IQR 19-30), with 355 (78%) females and 97 (21%) males. Most participants were White (407 [90%]). Participants in the immediate tonsillectomy group had fewer days of sore throat during 24 months than those in the conservative management group (median 23 days [IQR 11-46] vs 30 days [14-65]). After adjustment for site and baseline severity, the incident rate ratio of total sore throat days in the immediate tonsillectomy group (n=224) compared with the conservative management group (n=205) was 0·53 (95% CI 0·43 to 0·65; <0·0001). 191 adverse events in 90 (39%) of 231 participants were deemed related to tonsillectomy. The most common adverse event was bleeding (54 events in 44 [19%] participants). No deaths occurred during the study.
INTERPRETATION
Compared with conservative management, immediate tonsillectomy is clinically effective and cost-effective in adults with recurrent acute tonsillitis.
FUNDING
National Institute for Health Research.

Identifiants

pubmed: 37209706
pii: S0140-6736(23)00519-6
doi: 10.1016/S0140-6736(23)00519-6
pii:
doi:

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2051-2059

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests DDS reports grants or contracts from National Institute for Health Research (NIHR), Yorkshire Cancer Research, Innovate UK, Heart Research UK, and Cancer Research UK; payment or honoraria from University of Liverpool and University of Leicester; support for attending meetings or travel (or both) from AntiCancer Fund and Royal College of Surgeons of England; and participation on a data safety monitoring board or advisory board as a statistician and chair for NIHR. JAW reports support for attending meetings or travel (or both) from ENT Scotland. SC reports a leadership or fiduciary role for ENT UK. All other authors declare no competing interests.

Auteurs

Janet A Wilson (JA)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

James O'Hara (J)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK; Ear, Nose, and Throat Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: james.o'hara@newcastle.ac.uk.

Tony Fouweather (T)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Tara Homer (T)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Deborah D Stocken (DD)

Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.

Luke Vale (L)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Catherine Haighton (C)

Department of Social Work, Education, and Community Wellbeing, Northumbria University, Newcastle upon Tyne, UK.

Nikki Rousseau (N)

Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.

Rebecca Wilson (R)

Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

Lorraine McSweeney (L)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Scott Wilkes (S)

School of Medicine Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK.

Jill Morrison (J)

Senate Office, University of Glasgow, Glasgow, UK.

Kenneth MacKenzie (K)

Department of Ear, Nose, and Throat Surgery, NHS Greater Glasgow and Clyde, Glasgow, UK.

Kim Ah-See (K)

Department of Otolaryngology Head and Neck Surgery, NHS Grampian, Aberdeen, UK.

Sean Carrie (S)

Ear, Nose, and Throat Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Claire Hopkins (C)

Ear, Nose and Throat Department and Head and Neck Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Nicola Howe (N)

Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

Musheer Hussain (M)

School of Medicine, Dundee University, Dundee, UK.

Hisham Mehanna (H)

Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, UK.

Christopher Raine (C)

Ear, Nose, and Throat Department, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

Frank Sullivan (F)

Population and Behavioural Science Division, School of Medicine, University of St Andrews, St Andrews, UK.

Alexander von Wilamowitz-Moellendorff (A)

Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

M Dawn Teare (MD)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH